Compare VTAK & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTAK | LABT |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.6M |
| IPO Year | 2018 | N/A |
| Metric | VTAK | LABT |
|---|---|---|
| Price | $0.49 | $1.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.4M | 253.1K |
| Earning Date | 08-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $442,000.00 | N/A |
| Revenue This Year | $1,170.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3057.14 | N/A |
| 52 Week Low | $0.15 | $1.66 |
| 52 Week High | $4.31 | $4.72 |
| Indicator | VTAK | LABT |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 26.54 |
| Support Level | N/A | $1.88 |
| Resistance Level | $1.22 | $2.92 |
| Average True Range (ATR) | 0.17 | 0.43 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 12.86 | 12.50 |
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.